Sargramostim

Information about Sargramostim

Granulocyte colony stimulating factor (G-CSF) and granulocyte-macrophage colony stimulating factor (GM-CSF) are glycosylated polypeptides that induce an increase in the proliferation and maturation of white blood cells including neutrophils and monocytes-macrophages. Recombinant forms of these colony stimulating factors are used to treat severe neutropenia in patients receiving cancer chemotherapy or undergoing hematopoietic cell transplantation.

List of Sargramostim

Recombinant forms include filgrastim (G-CSF) and sargramostim (GM-CSF), both of which are commercially available for therapy of severe neutropenia and bone marrow failure.

Liver safety of Sargramostim

Neither filgrastim nor sargramostim have been linked to serum enzyme elevations during therapy or to clinically apparent liver injury.

Mechanism of action of Sargramostim

Sargramostim (sar gra' moe stim) is a recombinant form of granulocyte-macrophage stimulating factor (GM-CSF) that stimulates the proliferation and maturation of neutrophils and macrophages. Sargramostim is prepared in yeast (S. cerevisae) and is a 127 amino acid glycoprotein that is 98% identical to native, human GM-CSF. Sargramostim increases the number and activity of circulating neutrophils and monocytes.

FDA approval information for Sargramostim

Sargramostim was approved in the United States in 1991 for use in patients with acute myelogenous leukemia after chemotherapy induced neutropenia. Current indications also include support of patients undergoing hematopoietic cell transplantation as well as for patients undergoing autologous peripheral blood progenitor (stem) cell collection.

Dosage and administration for Sargramostim

Sargramostim is available in liquid and lyophilized forms under the brand names Leukine and Prokine. Sargramostim is given either intravenously or subcutaneously daily or three times weekly, the dose and regimen varying by indication.

Side effects of Sargramostim

Common side effects include fever, headache, fatigue, bone pain, nausea and weakness, but similar rates of these symptoms are reported with placebo or comparator therapies. Hematologic Agents Eculizumab, Emapalumab, Emicizumab, Lanadelumab, Ravulizumab

Hematologic Growth Factors

• Granulocyte colony stimulating factors
  • Filgrastim, Pegfilgrastim

• Granulocyte-Macrophage Colony Stimulating Factors
  • Sargramostim

• Erythropoiesis stimulating agents
  • Epoetin, Darbepoetin, Peginesatide

Thrombopoietin receptor agonists and Thrombopoiesis Stimulators

• • Avatrombopag, Eltrombopag, Fostamatinib, Lusutrombopag, Romiplostim, Oprelvekin (IL-11)

• Dailymed label info on Sargramostim
• FDA Sargramostim